In vitro and in vivo antitumor effects of lupeol-loaded galactosylated liposomes

References

• Abe K, Nozaki A, Tamura K, et al. (2007). Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol Immunol 51:117–25.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Venook AP. (2008). The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep 10:199–205.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36–48.
   PubMed Web of Science ®Google Scholar
• Bardania H, Tarvirdipour S, Dorkoosh F. (2017). Liposome-targeted delivery for highly potent drugs. Artif Cells Nanomed Biotechnol 45:1478–89.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. (2015). Liposomes as nanomedical devices. Int J Nanomed 10:975–99.
   PubMed Web of Science ®Google Scholar
• Cai L, Wang X, Wang W, et al. (2012). Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo. Int J Nanomed 7:4499–510.
   PubMed Web of Science ®Google Scholar
• Chaturvedi PK, Bhui K, Shukla Y. (2008). Lupeol: connotations for chemoprevention. Cancer Lett 263:1–13.
   PubMed Web of Science ®Google Scholar
• Chen X, Calvisi DF. (2014). Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol 184:912–23.
   PubMed Web of Science ®Google Scholar
• Dong H, Tian L, Gao M, et al. (2017). Promising galactose-decorated biodegradable poloxamer 188-PLGA diblock copolymer nanoparticles of resibufogenin for enhancing liver cancer therapy. Drug Deliv 24:1302–16.
   PubMed Web of Science ®Google Scholar
• D'Souza AA, Devarajan PV. (2015). Asialoglycoprotein receptor mediated hepatocyte targeting – strategies and applications. J Control Release 203:126–39. (
   PubMed Web of Science ®Google Scholar
• Fang X, Yang D, Luo H, et al. (2017). SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2. J Mol Cell Biol 9:243–55.
   PubMed Web of Science ®Google Scholar
• Fu H-W, Lin X, Zhu Y-X, et al. (2019). Circ-IGF1R has pro-proliferative and anti-apoptotic effects in HCC by activating the PI3K/AKT pathway. Gene 716:144031.
   PubMed Web of Science ®Google Scholar
• Gedaly R, Angulo P, Hundley J, et al. (2012). PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res 176:542–8.
   PubMed Web of Science ®Google Scholar
• Hagiwara K, Kurihara K, Honma M, et al. (2018). PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect. J Biomater Sci Polym Ed 29:448–59.
   PubMed Web of Science ®Google Scholar
• Heath TD, Brown CS. (1989). Targeted drug delivery: a two-compartment growth inhibition assay demonstrates that fluorodeoxyuridine and fluorodeoxyuridine monophosphate are liposome-independent drugs. Sel Cancer Ther 5:179–84.
   PubMedGoogle Scholar
• Jiang S, Wang Q, Feng M, et al. (2017). C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. Appl Microbiol Biotechnol 101:1535–46.
   PubMed Web of Science ®Google Scholar
• Lee TKW, Castilho A, Cheung VCH, et al. (2011). Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 53:160–70.
   PubMed Web of Science ®Google Scholar
• Li W, Shi J, Zhang C, et al. (2014). Co-delivery of thioredoxin 1 shRNA and doxorubicin by folate-targeted gemini surfactant-based cationic liposomes to sensitize hepatocellular carcinoma cells. J Mater Chem B 2:4901–10.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. (2003). Hepatocellular carcinoma. Lancet 362:1907–17.
   PubMed Web of Science ®Google Scholar
• Luo LM, Huang Y, Zhao BX, et al. (2013). Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials 34:1102–14.
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71–9.
   PubMed Web of Science ®Google Scholar
• Mcabee DD, Bennatt DJ, Ling YY. (1998). Identification and analysis of a CA(2+)-dependent lactoferrin receptor in rat liver. Lactoferrin binds to the asialoglycoprotein receptor in a galactose-independent manner. Adv Exp Med Biol 443:113–21.
   PubMed Web of Science ®Google Scholar
• Mcabee DD, Jiang X, Walsh KB. (2000). Lactoferrin binding to the rat asialoglycoprotein receptor requires the receptor's lectin properties. Biochem J 348:113–7.
   PubMed Web of Science ®Google Scholar
• Mishra N, Yadav NP, Rai VK, et al. (2013). Efficient hepatic delivery of drugs: novel strategies and their significance. Biomed Res Int 2013:382184. (
   PubMed Web of Science ®Google Scholar
• Nair AB, Shah J, Al-Dhubiab BE, et al. (2019). Development of asialoglycoprotein receptor-targeted nanoparticles for selective delivery of gemcitabine to hepatocellular carcinoma. Molecules 24:4566.
   PubMed Web of Science ®Google Scholar
• Oh HR, Jo HY, Park JS, et al. (2016). Galactosylated liposomes for targeted co-delivery of doxorubicin/vimentin siRNA to hepatocellular carcinoma. Nanomaterials 6:141.
   Web of Science ®Google Scholar
• Pathak A, Vyas SP, Gupta KC. (2008). Nano-vectors for efficient liver specific gene transfer. Int J Nanomed 3:31–49.
   PubMed Web of Science ®Google Scholar
• Peng J, Wang K, Tan W, et al. (2007). Identification of live liver cancer cells in a mixed cell system using galactose-conjugated fluorescent nanoparticles. Talanta 71:833–40.
   PubMed Web of Science ®Google Scholar
• Poelstra K, Prakash J, Beljaars L. (2012). Drug targeting to the diseased liver. J Control Release 161:188–97.
   PubMed Web of Science ®Google Scholar
• Prasad S, Madan E, Nigam N, et al. (2009). Induction of apoptosis by lupeol in human epidermoid carcinoma A431 cells through regulation of mitochondrial, Akt/PKB and NFkappaB signaling pathways. Cancer Biol Ther 8:1632–9.
   PubMed Web of Science ®Google Scholar
• Saleem M. (2009). Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett 285:109–15.
   PubMed Web of Science ®Google Scholar
• Shen YA, Shyu IL, Lu M, et al. (2015). Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control. Int J Nanomed 10:2485–502.
   PubMed Web of Science ®Google Scholar
• Siddique HR, Saleem M. (2011). Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sci 88:285–93.
   PubMed Web of Science ®Google Scholar
• Sui Y, Zheng X, Zhao D. (2015). Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway. Tumour Biol 36:8661–70.
   PubMedGoogle Scholar
• Sun L, Wang L, Chen T, et al. (2019). microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC. J Cell Mol Med 23:8292–304.
   PubMed Web of Science ®Google Scholar
• Thomas MB, O'Beirne JP, Furuse J, et al. (2008). Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 15:1008–14.
   PubMed Web of Science ®Google Scholar
• Varela M, Sala M, Llovet JM, et al. (2003). Treatment of hepatocellular carcinoma: is there an optimal strategy?. Cancer Treat Rev 29:99–104.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang X, Han J, et al. (2013). Extract of Perilla frutescens inhibits tumor proliferation of HCC via PI3K/AKT signal pathway. Afr J Tradit Complement Altern Med 10:251–7.
   PubMedGoogle Scholar
• Warczynski P, Gil J, Szmigielski S, et al. (1997). Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial. Anticancer Res 17:1223–6.
   PubMed Web of Science ®Google Scholar
• Ward PP, Conneely OM (2004). Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals 17:203–8.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Umehara T, Yasui F, et al. (2007). Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J Hepatol 47:744–50.
   PubMed Web of Science ®Google Scholar
• Weeke-Klimp AH, Bartsch M, Morselt HW, et al. (2007). Targeting of stabilized plasmid lipid particles to hepatocytes in vivo by means of coupled lactoferrin. J Drug Target 15:585–94.
   PubMed Web of Science ®Google Scholar
• Wei M, Xu Y, Zou Q, et al. (2012). Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci 46:131–41.
   PubMed Web of Science ®Google Scholar
• Wu W-d, Yi X-l, Jiang L-x, et al. (2015). The targeted-liposome delivery system of antitumor drugs. Curr Drug Metab 16:894–910.
   PubMed Web of Science ®Google Scholar
• Yu KF, Zhang WQ, Luo LM, et al. (2013). The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomed 8:2473–85.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang X, Zeng C, et al. (2019). Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR). Bioorg Med Chem 27:2187–91.
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhuang S, Qi XR. (2011). Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomed 6:3087–98.
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang M, Yung B, et al. (2012). Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomed 7:5465–74.
   PubMed Web of Science ®Google Scholar